The EMPA-REG outcome trial in 7020 patients with type 2 diabetes, which evaluated the oral sodium-glucose cotransporter 2 inhibitor empagliflozin, is the only study thus far showing a risk reduction (of 14 %) in MACE (risk ratio of 0.86 [95 % CI, 0.74 to 0.99]), while an additional benefit was observed in hospitalizations for heart failure [28]. The gene discussed is SLC5A2; the disease is heart failure.